Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (224)	8/26/2000 12:10:37 PM
From: scaram(o)uche	Respond to of 2243

Drat! Made a mistake some place. I "sold" 2K shares of NBSC from "trickle" to get back to the traditional "no margin" stance. The closing bid was $7, so there was 1/16 per share profit. I therefore added $125 to the cash balance. However.... given the original stake (100K) and the profits taken to date, the "total cost" should now be 100,525 instead of 99,275....... siliconinvestor.com Urg. Oh well.... unless someone can spot the error and suggest a simple fix, it's not worth worrying about. I'll just scrap the "trickle" portfolio, noting the picks and original prices. In a couple of months, however, the talking heads on CNBC and the "Jurbaks" of the world will start to pick "trickle" companies. I picked TECH (at a split-adjusted $15) in an article for Microsoft Investor, 9/15/97, and that "trickle" pick didn't have nearly the rationale to back it that we have today. It has, of course, underperformed relative to "therapeutics" picks. Still..... in any other environment.... a ten-bagger in less than three years for a reagents company?..... shows the potential for "trickle logic".